Mexico Genotyping Market Size & Outlook, 2023-2030
Mexico genotyping market, 2018-2030 (US$M)
Related Markets
Mexico genotyping market highlights
- The Mexico genotyping market generated a revenue of USD 161.4 million in 2023 and is expected to reach USD 383.6 million by 2030.
- The Mexico market is expected to grow at a CAGR of 13.2% from 2024 to 2030.
- In terms of segment, reagents & kits was the largest revenue generating product in 2023.
- Reagents & kits is the most lucrative product segment registering the fastest growth during the forecast period.
Genotyping market data book summary
| Market revenue in 2023 | USD 161.4 million |
| Market revenue in 2030 | USD 383.6 million |
| Growth rate | 13.2% (CAGR from 2023 to 2030) |
| Largest segment | Reagents & kits |
| Fastest growing segment | Reagents & kits |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Reagents & kits, Services |
| Key market players worldwide | Illumina Inc, Thermo Fisher Scientific Inc, Qiagen NV, Roche, Fluidigm Corporation, Danaher Corp, Agilent Technologies, Eurofins Scientific SE, GE HealthCare Technologies Inc Common Stock, Bio-Rad Laboratories Inc |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.9% of the global genotyping market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil genotyping market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 383.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Genotyping Market Scope
Genotyping Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico genotyping market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genotyping market will help companies and investors design strategic landscapes.
Reagents & kits was the largest segment with a revenue share of 61.21% in 2023. Horizon Databook has segmented the Mexico genotyping market based on instruments, reagents & kits, services covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico’s favorable government regulations pertaining to the approval of IVDs are expected to boost the market. In Mexico, COFEPRIS, a division of Mexican Ministry of Health, governs the approval process for IVDs. In 2017, it up-classified most of the IVD products and clearly defined medical devices regulations.
Increasing prevalence of cervical cancer is anticipated to drive the market. According to WHO, the number of new cases of cervical cancer in Mexico was expected to be around 9,439 in 2020. Owing to presence of favorable policies and unmet needs, several global players are operating in this country.
For instance, Roche has substantial presence in the Mexican market, with products such as cobas HCV GT for cervical cancer diagnosis. Similarly, other players, such as BD, also have market presence in this country. For instance, BD provides several products such as BD Onclarity HPV assay with genotyping capabilities for cervical cancer diagnosis.
Reasons to subscribe to Mexico genotyping market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Mexico genotyping market databook
-
Our clientele includes a mix of genotyping market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico genotyping market , including forecasts for subscribers. This country databook contains high-level insights into Mexico genotyping market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Mexico genotyping market size, by product, 2018-2030 (US$M)
Mexico Genotyping Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
